Synaptic loss and amyloid beta alterations in the rodent hippocampus induced by streptozotocin injection into the cisterna magna
10.1186/s42826-020-00049-x
- Author:
Yujin AHN
1
;
Jincheol SEO
;
Junghyung PARK
;
Jinyoung WON
;
Hyeon-Gu YEO
;
Keonwoo KIM
;
Chang-Yeop JEON
;
Jae-Won HUH
;
Sang-Rae LEE
;
Dong-Seok LEE
;
Youngjeon LEE
Author Information
1. National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Korea
- Publication Type:Research
- From:Laboratory Animal Research
2020;36(2):134-139
- CountryRepublic of Korea
-
Abstract:
To date, researchers have developed various animal models of Alzheimer’s disease (AD) to investigate its mechanisms and to identify potential therapeutic treatments. A widely recognized model that mimics the pathology of human sporadic AD involves intracerebroventricular (ICV) injection with streptozotocin (STZ). However, ICV injections are an invasive approach, which creates limitations in generalizing the results. In this study, we produced a rodent model of AD using STZ (3 mg/kg) injection via the cisterna magna (CM) once every week for 4 weeks, and analyzed at 4 weeks and 16 weeks after final injection. In the CM-STZ rodent model of AD, we observed increase in extracellular amyloid-beta (Aβ) deposition and decrease and abnormal morphology of post-synaptic protein, PSD95 in 16 weeks STZ-injected group. The model developed using our less-invasive method induced features of AD-like pathology, including significantly increased extracellular amyloid-beta deposition, and decreased synaptic protein in the hippocampus. These findings supporting the success of this alternative approach, and thus, we suggest this is a promising, less invasive model for use in future AD research.
